A polymeric nanoformulation improves the bioavailability and efficacy of sorafenib for hepatocellular carcinoma therapy
نویسندگان
چکیده
A nanoparticle-based formulation of sorafenib (NP-sfb) significantly inhibited hepatocellular carcinoma by suppressing angiogenesis and promoting cytotoxic T lymphocyte infiltration.
منابع مشابه
Sorafenib, a systemic therapy for hepatocellular carcinoma.
Hepatocellular carcinoma is a lethal disease that requires a multidisciplinary approach and management. Surgical therapy offers long-term survival; however, few patients are candidates. There has been no accepted systemic therapy for this disease until recently. This article briefly discusses the role of RAS/RAF/MEK/ERK signaling pathway in the pathogenesis of the disease and the promising role...
متن کاملMeta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
PURPOSE By carrying out a meta-analysis of randomized controlled trials that compared sorafenib or combined chemotherapy with placebo or combined chemotherapy, the effectiveness of sorafenib in hepatocellular carcinoma was evaluated in the present study, which also provided clinical practice guidelines of evidence-based-medicine. METHODS We reviewed PubMed citations concerning sorafenib treat...
متن کاملSorafenib Improves Survival in Metastatic Hepatocellular Carcinoma: A Case Report
Hepatocellular carcinoma (HCC) is a very common cancer. Curative treatments and local ones are well validated. Sorafenib, a multi-kinase receptor inhibitor was introduced in 2007 for advanced HCC in patients with preserved liver function. HCC is known to be resistant to systemic chemotherapy, and there are no validated therapies improving survival for metastatic disease. Herein, we report a cas...
متن کاملTarget therapy for hepatocellular carcinoma: is sorafenib for everybody?
Hepatocellular carcinoma (HCC) is a relevant health problem, being the sixth most common cancer worldwide in terms of incidence with 626,200 new cases per year, accounting for 5.7% of all new cancer cases. Due to the poor prognosis of the disease, the number of deaths per year is almost the same as new cases (598,000), making HCC the third most common cause of cancer-related death. Prognosis an...
متن کاملSorafenib in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fi fth most common malignancy worldwide with approximately 500,000 new cases per year, ranking as the third cause of cancer deaths. Until the very recent past no systemic therapy was available for patients with advanced HCC. However, advances achieved in the understanding of the molecular cancer biology and the subsequent introduction of molecularly targete...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomaterials Science
سال: 2021
ISSN: ['2047-4849', '2047-4830']
DOI: https://doi.org/10.1039/d0bm01881c